Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: Contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 1, 2008, Pages 98-104

  Okumura, Ryo ^a,b   Hirata, Tsuyoshi ^a   Onodera, Yoshikuni ^a   Hoshino, Kazuki ^a   Otani, Tsuyoshi ^a   Yamamoto, Tomoko ^b  

^a DAIICHI SANKYO CO   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Dual activity; MPC; Quinolones

Indexed keywords

7 (7 AMINO 7 METHYL 5 AZASPIRO(2.4)HEPTAN 5 YL) 6 FLUORO 1 (2 FLUORO 1 CYCLOPROPYL) 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; CLINAFLOXACIN; DC 159A; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; ENZYME ASSAY; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE; WILD TYPE;

AMINOPYRIDINES; ANTI-BACTERIAL AGENTS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MUTATION; QUINOLONES; STREPTOCOCCUS PNEUMONIAE;

EID: 43449112181     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn136     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention (CDC). Assessment of susceptibility testing practices for Streptococcus pneumoniae - United States, February 2000. MMWR Morb Mortal Wkly Rep 2002; 51: 392-4.
2. Draghi DC, Jones ME, Sahm DF et al. Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: Findings of the FAST surveillance initiative (2003 - 2004). Int J Antimicrob Agents 2006; 28: 525-31.
3. Powis J, McGeer A, Green K et al. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother 2004; 48: 3305-11.
4. Yamaguchi K, Ohno A; Levofloxacin Surveillance Group. Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: A longitudinal analysis from 1994 to 2002. Diagn Microbiol Infect Dis 2005; 52: 135-43.
5. Goldsmith CE, Moore JE, Murphy PG et al. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland. J Antimicrob Chemother 1998; 41: 420-1.
6. Ho PL, Yung RW, Tsang DN et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: Results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001; 48: 659-65.
7. Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: Results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001; 45: 3334-40.
8. Weiss K, Tillotson GS. Fluoroquinolones for respiratory infection: Too valuable to overuse (and too valuable to misuse!). Chest 2002; 122: 1102-3.
9. Khodursky AB, Peter BJ, Schmid MB et al. Analysis of topoisomerase function in bacterial replication fork movement: Use of DNA microarrays. Proc Natl Acad Sci USA 2000; 97: 9419-24.
10. Levine C, Hiasa H, Marians KJ. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim Biophys Acta 1998; 1400: 29-43.
11. Piddock LJ, Johnson MM. Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46: 813-20.
12. Zhanel GG, Walkty A, Nichol K et al. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn Microbiol Infect Dis 2003; 45: 63-7.
13. Lim S, Bast D, McGeer A et al. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: Redefining fluoroquinolone resistance. Emerg Infect Dis 2003; 9: 833-7.
14. Davies TA, Evangelista A, Pfleger S et al. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob Agents Chemother 2002; 46: 119-24.
15. Kays MB, Zhanel GG, Reimann MA et al. Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation. Pharmacotherapy 2007; 27: 221-6.
16. Dong Y, Zhao X, Domagala J et al. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 1756-8.
17. Hoshino K, Inoue K, Murakami Y et al. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob Agents Chemother 2008; 52: 65-76.
18. Sato K, Hoshino K, Tanaka M et al. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother 1992; 36: 1491-8.
19. Touyama M, Higa F, Nakasone C et al. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV. J Antimicrob Chemother 2006; 58: 1279-82.
20. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Sixth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003.
21. Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob Agents Chemother 2002; 46: 522-4.
22. Onodera Y, Uchida Y, Tanaka M et al. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae. J Antimicrob Chemother 1999; 44: 533-6.
23. Tanaka M, Sato K, Kimura Y et al. Inhibition by quinolones of DNA gyrase from Staphylococcus aureus. Antimicrob Agents Chemother 1991; 35: 1489-91.
24. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 410-2.
25. Drugeon HB, Juvin ME, Bryskier A. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: Comparison with ciprofloxacin, sparfloxacin and ofloxacin. J Antimicrob Chemother 1999; 43 Suppl C: 55-9.
26. Smith HJ, Nichol KA, Hoban DJ et al. Dual activity of fluoroquinolones against Streptocoocus pneumoniae: The facts behind the claims. J Antimicrob Chemother 2002; 49: 893-5.
27. Morrissey I, George J. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins. Antimicrob Agents Chemother 1999; 43: 2579-85.
28. Allen GP, Kaatz GW, Rybak MJ. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47: 2606-14.
29. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001; 33 Suppl 3: S147-56.
30. Kishii R, Takei M, Fukuda H et al. Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47 77-81.
31. Strahilevitz J, Hooper DC. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: Direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother 2005; 49: 1949-56.
32. Ince D, Zhang X, Silver LC et al. Dual targeting of DNA gyrase and topoisomerase IV: Target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother 2002; 46: 3370-80.
33. Jorgensen JH, Weigel LM, Ferraro MJ et al. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob Agents Chemother 1999; 43: 329-34.
34. Pestova E, Millichap JJ, Noskin GA et al. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones. J Antimicrob Chemother 2000; 45: 583-90.
35. Kawamura-Sato K, Hasegawa T, Torii K et al. Prevalence of lle-460-Val/ParE substitution in clinical Streptococcus pneumoniae isolates that were less susceptible to fluoroquinolones. Curr Microbiol 2005; 51: 27-30.